<DOC>
	<DOCNO>NCT00623649</DOCNO>
	<brief_summary>The purpose study determine whether 3-day course therapy orally administer VCH-916 give different dosage effectively reduce amount circulate virus ( i.e. , viral load ) patient early-stage chronic hepatitis C-infection . This study also evaluate safety tolerability treatment VCH-916 . Blood sample also take measure level VCH-916 present plasma various time point treatment period .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Multiple Ascending Doses VCH 916 Subjects With Chronic Hep C Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>Males females 18 60 year age No evidence cirrhosis liver fibrosis correspond Metavir Stages 0 3 Subject 's liver disease stable ALT value &lt; 5 X ULN Serologic evidence detectable plasma HCVRNA ≥ 100,000 IU/ml screening Documented HCV Genotype 1 chronic hepatitis C. Judged good health basis medical history physical examination All hematology clinical chemistry must within normal limit show clinically significant abnormality . Be treatmentnaïve experience . For female subject , must pregnant breastfeeding must postmenopausal , surgically sterile , abstinent , use two proven method birth control . Sexually active male subject , must practice acceptable method contraception treatment period Female subject childbearing potential must negative serum ßHCG pregnancy test screen negative urine pregnancy test Day 1 first dose study drug . Agree participate clinical trial duration his/her participation clinical trial . Be participate clinical study participate another clinical trial within last 30 day study drug administration , participation 2 drug study last 12 month ( exclusive current study ) . Be actively take hard illicit drug within 12 month prior screen visit alcohol . Have ChildPugh score &gt; 5 . Have evidence liver cirrhosis include histological evidence hepatic cirrhosis liver biopsy . Have cause liver disease chronic hepatitis Cinfection Active malignant disease suspicion history malignant disease within five previous year ( except adequately treat basal cell carcinoma ) . Have clinically significant electrocardiogram abnormality and/or cardiovascular dysfunction within previous 6 month Have significant renal , pulmonary , gastrointestinal absorption , neurological disease , neoplasia . Have history psychiatric disorder determine investigator contraindicate therapy . Have uncontrolled Type 1 Type II diabetes . Antinuclear antibody titer ≥1:320 . Coinfection hepatitis B and/or HIV 1 HIV 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>